source
- Kodiak Sciences reports Phase 3 success for Zenkuda, matching Eylea in wet AMDKodiak Sciences announced that its experimental therapy Zenkuda achieved comparable efficacy to the market‑leading anti‑VEGF drug Eylea in a late‑stage trial for wet age‑related macular degeneratio…
- Nonprofits launch ultra-rare immune disease gene therapy Waskyra at $3.25 million priceTwo nonprofit organizations have received FDA approval for a gene therapy that targets an ultra-rare immune disorder. The therapy, called Waskyra, is now being launched with a list price of $3.25…